A Randomised, Double-blinded, Single Subcutaneous Dose Escalation Trial Investigating the Safety and Tolerability of NNC9204-1513 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Jul 2018
Price : $35 *
At a glance
- Drugs NN-9513 (Primary) ; Glucagon
- Indications Hypoglycaemia
- Focus Adverse reactions; First in man
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 25 Jun 2018 Status changed from suspended to completed.
- 14 Jun 2018 Status changed from recruiting to suspended due to Evaluation of data..